The Supreme Court reserved its verdict on 27 October 2026 after questioning how a cancer injection available to a dealer for Rs 11,000 could be charged to a patient at Rs 1.30 lakh. A bench of Justices Vikram Nath and Sandeep Mehta heard two petitions about the gap between the maximum retail price printed on medicines and the much lower prices paid by retailers and hospitals. The judges asked why margin controls should stop at cancer treatment, and they suggested considering a uniform 16 per cent cap across medicines. No date was given for the judgment.
Justice Sandeep Mehta raised the example of a medical dealer whose wife was undergoing treatment at a hospital. The dealer price for the injection was Rs 11,000, according to the account given in court. The hospital refused to administer an injection brought by the dealer and charged Rs 1.30 lakh for the injection. The bench asked the Centre to justify the difference, and it asked where the money went.
Cancer medicines and the 30 per cent cap
The immediate policy at issue is a 30 per cent trade margin cap covering 137 cancer medicines, with revised prices due to take effect on 9 November. A trade margin cap limits the share of the price that can be kept as margin between the purchase price and the sale price. Under the cap, the revised prices for those 137 medicines are meant to bring the price paid by patients closer to the price at which the medicines are bought.
The Centre estimates annual patient savings of about Rs 2,500 crore from the cap on those medicines. That figure is an estimate, not a sum already saved, because the revised prices are due to take effect on 9 November. The savings, if the estimate holds, would come from lower prices on the medicines covered, spread across the patients who buy them in a year. The estimate does not cover medicines outside the list of 137, and it does not cover other parts of a hospital bill.
Cancer treatment and wider price controls
The judges asked why margin controls should stop at cancer treatment. Their question points to a wider issue in medicine pricing: many medicines sit outside strict price control, and their MRPs are set by manufacturers within rules that limit later price rises but do not set the first price. Scheduled medicines, by contrast, face ceiling prices under the Drugs (Prices Control) Order. The court questioned why a large share of medicines remains outside that stricter regime.
During the hearing, the bench suggested considering a uniform 16 per cent cap across medicines. A uniform cap would apply the same margin limit to medicines beyond the cancer list, rather than setting different limits for different groups. The suggestion was raised during the hearing, and it is not a judgment. The court reserved its verdict, which means it will give its decision at a later date that has not been announced. Until that decision is given, the suggestion has no legal force on its own.
The Centre defended its policy as a balance between affordability, availability and industry growth. That defence rests on a view that price control must keep medicines affordable for patients while keeping them available in shops and hospitals and keeping the industry able to make and supply them. The court pressed the Centre on that balance, asking why the need for industry growth should leave patients exposed to prices far above purchase prices. The exchange shows the two sides of the case: the patient price on one side and the supply chain on the other.
Cancer price gap and what happens next
What happens next depends on two separate tracks. One track is the government policy track, where revised prices for the 137 cancer medicines are due on 9 November under the 30 per cent cap. That track will change the prices of those medicines, within the terms of the cap, on the date given. The other track is the court track, where the verdict is reserved and no date has been given. The court decision, when it comes, could affect how pricing rules are applied more widely.
The hearing on 27 October did not decide the case. It reserved the verdict, it questioned the gap between a dealer price of Rs 11,000 and a patient price of Rs 1.30 lakh for one injection, it noted the 30 per cent cap on 137 cancer medicines with revised prices due on 9 November and an estimated annual saving of about Rs 2,500 crore, and it raised a uniform 16 per cent cap for consideration across medicines. No judgment date was given.